SLE: Systemic lupus erythematosus. Symptoms of systemic lupus ... Patients frequently suffer from symptoms the relation of which to active autoimmune inflammation has remained hard to determine ...

Cambridge, Massachusetts Thursday, October 17, 2024, 17:00 Hrs [IST] ...

Clinical stage biopharma Kezar Life Sciences is discontinuing its lupus nephritis (LN) clinical programme following the death ...

Completes Transition to Immune-Mediated Disease Focused CompanyHighlights Additional Data from Phase 1b Primary Membranous ...

The SRI incorporated components of the Systemic Lupus Erythematosus Disease Activity ... for suppression of active disease or for maintenance of remission, or both)? Will the drug be effective ...

About Systemic Lupus Erythematosus (SLE ... experiencing at least one flare per year or presenting persistently active disease, there is an unmet medical need in SLE for the development of ...

Genentech announced positive results from the Phase III study (REGENCY) of Gazyva (Obinutuzumab) for people with active lupus nephritis (LN ... onset idiopathic nephrotic syndrome, and systemic lupus ...

The company's PALIZADE study had enrolled 84 patients with active lupus nephritis, a kidney disease-related complication of systemic lupus erythematosus. Patients were dosed with either 30 mg of ...

The clinical hold doesn’t cover its drug’s Investigational New Drug application for autoimmune hepatitis, for which the Phase ...

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced the voluntary ...